Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
A retrovirus-derived vector called self-inactivating (SIN) vector was designed for the transduction of whole genes into mammalian cells. SIN vectors contain a deletion of 299 base pairs in the 3' long terminal repeat (LTR), which includes sequences encoding the enhancer and promoter functions. When viruses derived from such vectors were used to infect NIH 3T3 cells, the deletion was transferred to the 5' LTR, resulting in the transcriptional inactivation of the provirus in the infected cell. Introduction of a hybrid gene (human metallothionein-promoted c-fos) into cells via a SIN vector was not associated with rearrangements and led to the formation of an authentic mRNA transcript, which in some cases was induced by cadmium. SIN vectors should be particularly useful in gene transfer experiments designed to study the regulated expression of genes in mammalian cells. Absence of enhancer and promoter sequences in both LTRs of the integrated provirus should also minimize the possibility of activating cellular oncogenes and may provide a safer alternative to be used in human gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Lehrach, H., Diamond, D., Wozney, J. M., & Boedtker, H. (1977) · Biochemistry · doi:10.1021/bi00640a033 · Cited by 3,415
Mann, R., Mulligan, R. C., & Baltimore, D. (1983) · Cell · doi:10.1016/0092-8674(83)90344-6 · Cited by 1,805
Seiki, M., Hattori, S., Hirayama, Y., & Yoshida, M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3618 · Cited by 1,525
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells
Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., & Axel, R. (1977) · Cell · doi:10.1016/0092-8674(77)90333-6 · Cited by 1,352
Construction and applications of a highly transmissible murine retrovirus shuttle vector
Cepko, C. L., Roberts, B. E., & Mulligan, R. C. (1984) · Cell · doi:10.1016/0092-8674(84)90440-9 · Cited by 992
A new dominant hybrid selective marker for higher eukaryotic cells
Colbére-Garapin, F., Horodniceanu, F., Kourilsky, P., & Garapin, A.-C. (1981) · Journal of Molecular Biology · doi:10.1016/0022-2836(81)90321-1 · Cited by 618
Keller, G., Paige, C., Gilboa, E., & Wagner, E. F. (1985) · Nature · doi:10.1038/318149a0 · Cited by 572
Self-citationA restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance
Jorgensen, R. A., Rothstein, S. J., & Reznikoff, W. S. (1979) · Molecular and General Genetics MGG · doi:10.1007/bf00267254 · Cited by 571
Prospects for Human Gene Therapy
Anderson, W. F. (1984) · Science · doi:10.1126/science.6093246 · Cited by 533
Self-citation
Cited by
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“Removal of endogenous strong enhancer elements from lentiviral and g-retroviral vectors using a “self-inactivating” SIN design (29) is another approach that decreases the risk of genotoxicity (30); this design is used in most current clinical trials (Table 1).”
The c-fos protein interacts with c-JunAP-1 to stimulate transcription of AP-1 responsive genes
Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., & Karin, M. (1988) · Cell · doi:10.1016/0092-8674(88)90076-1 · Cited by 1,335
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
“Therefore, most SIN MLV vectors had a deletion only in the enhancer region, and transcriptional inactivation of the LTR was relatively inefficient (9, 20, 45, 54).”
BackgroundA Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses
Naviaux, R. K., Costanzi, E., Haas, M., & Verma, I. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5701-5705.1996 · Cited by 732
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Gene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
Progress Toward Human Gene Therapy
Friedmann, T. (1989) · Science · doi:10.1126/science.2660259 · Cited by 480
Viral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases
Walther, W., & Stein, U. (2000) · Drugs · doi:10.2165/00003495-200060020-00002 · Cited by 442
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1241 · Cited by 379
Viral vectors: from virology to transgene expression
Bouard, D., Alazard‐Dany, N., & Cosset, F. (2009) · British Journal of Pharmacology · doi:10.1038/bjp.2008.349 · Cited by 360
Gene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Occurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1122 · Cited by 344
Gene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 340
Lentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
Swift, S., Lorens, J., Achacoso, P., & Nolan, G. P. (1999) · Current Protocols in Immunology · doi:10.1002/0471142735.im1017cs31 · Cited by 313
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
Gene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267
Kitani, A., Fuss, I., Nakamura, K., Kumaki, F., Usui, T., & Strober, W. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030917 · Cited by 260
Genotoxicity of Retroviral Integration In Hematopoietic Cells
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.001 · Cited by 258
Gough, P. J., Garton, K. J., Wille, P. T., Rychlewski, M., Dempsey, P. J., & Raines, E. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3678 · Cited by 257
Expression of human class II major histocompatibility complex antigens using retrovirus vectors.
Korman, A. J., Frantz, J. D., Strominger, J. L., & Mulligan, R. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2150 · Cited by 252
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Gene therapy for severe combined immunodeficiency: are we there yet?
Cavazzana-Calvo, M., & Fischer, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30953 · Cited by 183
Biosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“Several important principles have emerged from the development of these vectors: (i) the split genome design to avoid the formation of replication-competent species in producer cells (Miller, 1990); (ii) the deletion of enhancer/promoter sequences from the long terminal repeats (LTRs) to generate so-called self-inacti…”
InfluentialSirven, A., Ravet, E., Charneau, P., Zennou, V., Coulombel, L., Guétard, D., Pflumio, F., & Dubart-Kupperschmitt, A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0282 · Cited by 163
Anson, D. S. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-9 · Cited by 154
Glycosylation of Human Apolipoprotein E
Wernette-Hammond, M. E., Lauer, S. J., Corsini, A., Walker, D., Taylor, J. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81907-x · Cited by 149
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors
Schambach, A., Galla, M., Maetzig, T., Loew, R., & Baum, C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300152 · Cited by 127
Protective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70
“. Secondly, the deletion in the 3′ LTR of the viral promoter and enhancer sequences in self-inactivating lentiviral vectors limits the likelihood of endogenous promoter activation”
BackgroundBai, Y., Soda, Y., Izawa, K., Tanabe, T., Kang, X., Tojo, A., Hoshino, H., Miyoshi, H., Asano, S., & Tani, K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302026 · Cited by 68
Hematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2012) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 54
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
Development of Gene Therapy for Thalassemia
Nienhuis, A. W., & Persons, D. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011833 · Cited by 38
“During retroviral integration, a portion of the 50 LTR is copied from the 30 LTR so that both LTRs lack the enhancer/promoter in the integrated SIN vector genome, thereby reducing the risk for proto-oncogene activation (Yu et al. 1986; Zufferey et al. 1998).”
BackgroundThe retroviral vector family: something for everyone
Elsner, C., & Bohne, J. (2017) · Virus Genes · doi:10.1007/s11262-017-1489-0 · Cited by 36
van der Loo, J. C. M., Swaney, W. P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., Baum, C., Thrasher, A. J., Williams, D. A., Nordling, D. L., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.102 · Cited by 34
Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza
Michelini, Z., Minkoff, J. M., Yang, J., Negri, D., Cara, A., Hanson, B. J., & Salvatore, M. (2020) · Viruses · doi:10.3390/v12121460 · Cited by 6
Metadata
- Authors
- Yu, S. F., von Rüden, T., Kantoff, P. W., Garber, C., Seiberg, M., Rüther, U., Anderson, W. F., Wagner, E. F., & Gilboa, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1986-05
- Volume
- 83
- Issue
- 10
- Pages
- 3194-3198
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2047942455
- Cited by
- 541
- References
- 27
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.